Neola Medical announces results of the rights issue
The subscription rate was 70 percent and the company receives approximately SEK 32.5 million before issue costs.
See the latest news and media coverage for Neola Medical. We track all announcements, press releases, and industry mentions in real time, all in one place.
Swedish medtech company developing neonatal lung monitoring
neolamedical.comLast updated
In short: Neola Medical reported successful clinical pilot safety results and secured $3.1 million in funding to advance its U.S. market strategy.
The subscription rate was 70 percent and the company receives approximately SEK 32.5 million before issue costs.
The subscription period ends on June 17, and investors are urged to act today.
CEO Hanna Sjöström discusses the capital raise to accelerate regulatory clearance and market entry.
The document relates to a new issue of SEK 46.8 million with preferential rights, subscription period June 3-17, 2026.
Earnings call Neola Medical closed 2025 with key clinical progress, including nearly completed pilot studies in Sweden and an IRB-approved U.S. trial site. Cost discipline...
Read the latest Neola Medical AB share news and breaking stories, covering the ST:NEOLA share price, results and market-moving developments. Our team of expert financial...
During the quarter, Neola Medical completed enrollment and reported positive safety results from its first clinical pilot study in preterm born babies in Sweden. The...
The medical technology company Neola Medical, active in lung monitoring of prematurely born children, has decided to carry out a rights issue of approximately...
Track Neola Medical and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.